Potential of afatinib in the treatment of patients with HER2-positive breast cancer

References

• CitriAYardenYEGF-ERBB signalling: towards the systems levelNat Rev Mol Cell Biol2006750551616829981
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol2001212713711252954
   PubMed Web of Science ®Google Scholar
• BaselgaJCortesJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med201236610911922149875
   PubMed Web of Science ®Google Scholar
• BlackwellPrimary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxaneJ Clin Oncol302012suppl abstr LBA1
   PubMedGoogle Scholar
• BlackwellKLBursteinHJStornioloAMRandomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerJ Clin Oncol2010281124113020124187
   PubMed Web of Science ®Google Scholar
• BursteinHJSunYDirixLYNeratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancerJ Clin Oncol2010281301130720142587
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med20063552733274317192538
   PubMed Web of Science ®Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene2008274702471118408761
   PubMed Web of Science ®Google Scholar
• MillerPhase IIB/III double-blind randomized trial of afatinib + best supportive care versus placebo + best supportive care in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX lung 1)Annals of Oncology21Supplement 8
   Google Scholar
• YamamotoNA phase II trial of afatinib in patients with advanced non-small cell lung cancer previously treated with erlotib or gefitinibJ Clin Oncol292011suppl abstr 7524
   PubMedGoogle Scholar
• YangJC-HSchulerMHYamamotoNLUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutationsASCO Meeting Abstracts201230LBA7500
   Google Scholar
• MinkovskyNBerezovABIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumorsCurr Opin Investig Drugs2008913361346
   PubMedGoogle Scholar
• EskensFAMomCHPlantingASA phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursBr J Cancer200898808518026190
   PubMed Web of Science ®Google Scholar
• YapTAVidalLAdamJPhase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumorsJ Clin Oncol2010283965397220679611
   PubMed Web of Science ®Google Scholar
• AngJA phase I study of daily BIBW 2992, an irreversible EGR7HER2 dual kinase inhibitor, in combination with weekly paclitaxelJ Clin Oncol272009suppl abstr e14541
   Google Scholar
• VermorkenJBMachielsJHRotteySPhase Ib study evaluating the combintion of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5FU (PF) in patients with advanced solid tumorsJ Clin Oncol282010suppl abstr e13521
   PubMedGoogle Scholar
• HollebecqueAPhase I trial to assess the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumorsJ Clin Oncol302012suppl abstr 3104
   Google Scholar
• SenellartHPhase I safety and tolerability of once daily oral afatinib (A) in combination with docetaxel (D) in patients (pts) with relapsed or refractory advanced solid tumors
   Google Scholar
• SenellartHPhase I safety and tolerability of once daily oral afatinib (A) in combination with docetaxel (D) in patients (pts) with relapsed or refractory advanced solid tumorsJ Clin Oncol302012suppl abstr e13010
   Google Scholar
• ShawHPlummerRVidalLA phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HeR2 receptoor tyrosine Kinase inhibitor, in patients with advanced solid tumorsJ Clin Oncol (Meeting Abstracts)200624(18S) Suppl3027
   Google Scholar
• LewisNMarshallJAmelsbergAA phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumorsJ Clin Oncol (Meeting Abstracts)200624(18S) Suppl3091
   Google Scholar
• HickishTUse of BIBW2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumabCancer Res20096924 Suppl Abstract nr 5060
   Web of Science ®Google Scholar
• LinNUWinerEPWheatleyDA phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabBreast Cancer Res Treat201213331057106522418700
   PubMed Web of Science ®Google Scholar
• HarbeckNBIBW2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapiesCancer Res20096924 Suppl Abstract nr 5062
   Web of Science ®Google Scholar
• RimawiMFAleixoSBAlarcon RozasAA neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC)ASCO Meeting Abstracts201230606
   Google Scholar
• GunzerKAddition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapyJ Clin Oncol2815s2010suppl abstr 1072
   PubMedGoogle Scholar
• Data from www.clinicaltrial.gov last update72012
   Google Scholar
• HickishTTsengLMMehtaAOLUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L)ASCO Meeting Abstracts201230TPS651
   Google Scholar
• OcanaAAmirEIrreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directionsCancer Treat Rev20093568569119733440
   PubMed Web of Science ®Google Scholar
• LinNUDierasVPaulDMulticenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancerClin Cancer Res2009151452145919228746
   PubMed Web of Science ®Google Scholar
• PestalozziBCBrignoliSTrastuzumab in CSFJ Clin Oncol2000182349235110829059
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol201213253222153890
   PubMed Web of Science ®Google Scholar
• BaselgaJBradburyIEidtmannHLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialLancet201237963364022257673
   PubMed Web of Science ®Google Scholar
• ChangJCNTBCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2 overexpressing breast cancerJ Clin Oncol292011suppl abstr 505
   Google Scholar
• HolmesFACorrelation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapyJ Clin Oncol292011suppl abstr 506
   PubMedGoogle Scholar